MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

Hui Li, Chia Wei Li, Xiaoqiang Li, Qingqing Ding, Lei Guo, Shuang Liu, Chunxiao Liu, Chien Chen Lai, Jung Mao Hsu, Qiongzhu Dong, Weiya Xia, Jennifer L. Hsu, Hirohito Yamaguchi, Yi Du, Yun Ju Lai, Xian Sun, Paul B. Koller, Qinghai Ye, Mien Chie Hung

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Background & Aims: Inhibitors of MET have not produced satisfactory outcomes in trials of patients with liver cancer. We investigated the mechanisms of liver tumor resistance to MET inhibitors in mice. Methods: We tested the effects of MET inhibitors tivantinib and capmatinib in the mouse hepatocellular carcinoma (HCC) cell line HCA-1 and in immune-competent and immunodeficient mice with subcutaneous tumors grown from this cell line. Tumors were collected from mice and tumor cells were analyzed by time-of-flight mass cytometry. We used short hairpin RNAs to weaken expression of MET in Hep3B, SK-HEP-1, HA59T, and HA22T liver cancer cell lines and analyzed cells by immunoblot, immunofluorescence, and immunoprecipitation assays. Mass spectrometry was used to assess interactions between MET and glycogen synthase kinase 3β (GSK3B), and GSK3B phosphorylation, in liver cancer cell lines. C57/BL6 mice with orthotopic tumors grown from Hep1-6 cells were given combinations of capmatinib or tivantinib and antibodies against programmed cell death 1 (PDCD1; also called PD1); tumors were collected and analyzed by immunofluorescence. We analyzed 268 HCCsamples in a tissue microarray by immunohistochemistry. Results: Exposure of liver cancer cell lines to MET inhibitors increased their expression of PD ligand 1 (PDL1) and inactivated cocultured T cells. MET phosphorylated and activated GSK3B at tyrosine 56, which decreased the expression of PDL1 by liver cancer cells. In orthotopic tumors grown in immune-competent mice, MET inhibitors decreased the antitumor activity of T cells. However, addition of anti-PD1 decreased orthotopic tumor growth and prolonged survival of mice compared with anti-PD1 or MET inhibitors alone. Tissue microarray analysis of HCC samples showed an inverse correlation between levels of MET and PDL1 and a positive correlation between levels of MET and phosphorylated GSK3B. Conclusions: In studies of liver cancer cell lines and mice with orthotopic tumors, MET mediated phosphorylation and activated GSK3B, leading to decreased expression of PDL1. Combined with a MET inhibitor, anti-PD1 and anti-PDL1 produced additive effect to slow growth of HCCs in mice.

Original languageEnglish (US)
Pages (from-to)1849-1861.e13
JournalGastroenterology
Volume156
Issue number6
DOIs
StatePublished - May 2019
Externally publishedYes

Keywords

  • Glycogen Synthase Kinase 3
  • Hepatocellular Carcinoma
  • Programmed Cell Death Ligand 1
  • Tumor Necrosis Factor Receptor-Associated Factor 6

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1'. Together they form a unique fingerprint.

  • Cite this

    Li, H., Li, C. W., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C. C., Hsu, J. M., Dong, Q., Xia, W., Hsu, J. L., Yamaguchi, H., Du, Y., Lai, Y. J., Sun, X., Koller, P. B., Ye, Q., & Hung, M. C. (2019). MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology, 156(6), 1849-1861.e13. https://doi.org/10.1053/j.gastro.2019.01.252